NVS. 3 gaps in 3 weeks. 12/15/12 Novartis

As the only pituitary-directed therapy, Signifor represents a novel therapeutic approach by addressing the underlying mechanism of Cushing's disease[1]

In the Phase III trial, most patients experienced a sustained decrease in mean urinary-free cortisol levels, a key measure of disease, with a subset normalizing[2]

In the EU, Signifor has been previously approved for the treatment of adult patients with Cushing's disease; other worldwide regulatory filings are underway

http://www.novartis.com/newsroom/media-releas...5290.shtml

Novartis drug Signifor® gains FDA approval as the first medication to treat Cushing's disease, a serious endocrine disorder